Physicians and researchers can use the new NGS Lung Panel to identify and monitor actionable biomarkers related to lung cancer. Credit: Steve Cross from Pixabay.

Molecular diagnostics maker Biocept has launched a new multi-gene liquid biopsy test called Target Selector NGS Lung Panel, for the detection of lung cancer.

The company’s Target Selector liquid biopsy platform is designed to capture and analyse tumour-associated molecular markers in circulating tumour cells (CTCs) and plasma (ctDNA).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Physicians and researchers can use the new NGS Lung Panel to identify and monitor actionable biomarkers related to lung cancer.

The panel runs on the Ion Torrent next generation sequencing (NGS) platform by Thermo Fisher Scientific.

Biocept said that the product integrates its laboratory and commercial infrastructure, blood sample preservation and DNA/RNA isolation expertise with Thermo Fisher’s NGS panel and informatics technology dubbed Oncomine.

Target Selector NGS Lung Panel includes biomarkers that are frequently used to make treatment decisions for cancer patients. It also features Thermo Fisher’s Oncomine Knowledge Reporter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biocept president and CEO Michael Nall said: “This new solution makes Biocept the only commercial liquid biopsy company that can offer customers the flexibility to order either a customised single biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired.

“Biocept is the only commercial liquid biopsy company that can offer customers the flexibility to order either a customised single biomarker assay or a larger NGS-based liquid biopsy test panel.”

“This new offering complements our existing Target Selector testing platform, which focuses on delivering actionable and cost-effective biomarker information to address needs of physicians, healthcare systems and payors as they develop personalised treatment protocols for patients diagnosed with cancer.”

Lung cancer is known to be the primary cause of cancer-related death in the US, with an estimated 155,870 deaths in 2017.

According to Biocept, clinical utility of liquid biopsy to obtain molecular information associated with the cancer can offer an effective approach for oncologists to select targeted treatments.

In July 2017, the company introduced a Target Selector platform-based liquid biopsy progesterone receptor (PR) test to detect and monitor select biomarkers in breast cancer patients.